(Q34075014)

30 July 2017

1 reference

title

New investigational antifungal agents for treating invasive fungal infections (English)

1 reference

invasive fungal infections

30 July 2017

main subject

1 reference

Hossain MA

1

1 reference

30 July 2017

Ghannoum MA

series ordinal

2

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 August 2000

1 reference

Expert Opinion on Investigational Drugs

30 July 2017

published in

1 reference

30 July 2017

volume

9

1 reference

30 July 2017

issue

8

1 reference

30 July 2017

page(s)

1797-1813

1 reference

Nosocomial bloodstream infections in United States hospitals: a three-year analysis

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

Cerebral phaeohyphomycosis caused by Ramichloridium obovoideum (Ramichloridium mackenziei): case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

Lipid formulations of amphotericin B: clinical efficacy and toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

A comparative review of conventional and lipid formulations of amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14 alpha-sterol demethylase purified from Candida albicans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

Oral azole drugs as systemic antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? The National Institute of Allergy and Infectious Diseases Mycoses stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

Molecular mechanisms of drug resistance in fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

Mode of Action of 5-Fluorocytosine and Mechanisms of Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

Mode of action of 5-fluorocytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

Pharmacokinetics of liposomal nystatin in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

Mild heating of amphotericin B-desoxycholate: effects on ultrastructure, in vitro activity and toxicity, and therapeutic efficacy in severe candidiasis in leukopenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

In-vitro and in-vivo activities of SCH56592 against Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

Efficacy of SCH56592 in a rabbit model of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei")

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

Antibiotics that inhibit fungal cell wall development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

Comparison of nikkomycin Z with amphotericin B and itraconazole for treatment of histoplasmosis in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

Activity of pradimicin BMS-181184 against Aspergillus spp

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

The in-vivo activity of an antifungal antibiotic, benanomicin A, in comparison with amphotericin B and fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5, and salivary mucin (MUC7) domain 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1797

10.1517/13543784.9.8.1797

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference